{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:52:36Z","timestamp":1781023956650,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.yebeh.2015.02.009","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T03:47:12Z","timestamp":1426132032000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Drug interactions involving antiepileptic drugs: Assessment of the consistency among three drug compendia and FDA-approved labels"],"prefix":"10.1016","volume":"44","author":[{"given":"Dana","family":"Ekstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matanya","family":"Tirosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Eyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.02.009_bb0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.wnl.0000341789.77291.8d","article-title":"Assessment of potential drug interactions in patients with epilepsy: impact of age and sex","volume":"72","author":"Gidal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Landmark","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.seizure.2007.02.006","article-title":"Clinical use of antiepileptic drugs at a referral centre for epilepsy","volume":"16","author":"Johannessen-Landmark","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0404.2006.00639.x","article-title":"Trends in utilization of antiepileptic drugs in Denmark","volume":"113","author":"Tsiropoulos","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1528-1167.2009.02512.x","article-title":"Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy","author":"Alexandre","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.yebeh.2013.09.041","article-title":"Concomitant therapy in people with epilepsy: potential drug-drug interactions and patient awareness","volume":"31","author":"Eyal","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2014.03.008","article-title":"Use of antiepileptic drugs and lipid-lowering agents in the United States","volume":"34","author":"Mintzer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yebeh.2013.06.031","article-title":"Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy","volume":"29","author":"Karouni","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0050","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","article-title":"A mechanistic approach to antiepileptic drug interactions","volume":"32","author":"Anderson","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0060","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs) \u2014 part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0065","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs) \u2014 part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jcph.269","article-title":"Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?","volume":"54","author":"Romo","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/clpt.2009.95","article-title":"Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium","volume":"86","author":"Anthony","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/clpt.2009.198","article-title":"Comparison of critical drug\u2013drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia","volume":"87","author":"Olvey","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","article-title":"Comparative assessment of four drug interaction compendia","volume":"63","author":"Vitry","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0090","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1345\/aph.1L255","article-title":"Clinically significant drug\u2013drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia","volume":"42","author":"Wong","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0095","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.sapharm.2005.06.005","article-title":"Comparison of potentially hepatotoxic drugs among major US drug compendia","volume":"1","author":"Guo","year":"2005","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0100","series-title":"Micromedex\u00ae Healthcare Series [Drug Interactions]","year":"2001"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0105","series-title":"Clinical Pharmacology [Drug Interactions].","year":"2006"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0110","series-title":"Lexicomp Online\u00ae, Lexi-Interact\u00ae","year":"2004"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ajhp\/61.4.380","article-title":"Evaluation of personal digital assistant software for drug interactions","volume":"61","author":"Barrons","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clpt.2005.03.007","article-title":"Personal digital assistant-based drug reference software as tools to improve rational prescribing: benchmark criteria and performance","volume":"78","author":"Knollmann","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0125","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"L\u00f6scher","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0135","series-title":"The Epilepsy Prescriber's Guide to Antiepileptic Drugs","author":"Patsalos","year":"2013"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00562061","article-title":"Pharmacokinetics of metformin after intravenous and oral administration to man","volume":"16","author":"Pentik\u00e4inen","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0155","unstructured":"Sanofi-Aventis. Rifadin (rifampin) product monograph, Revised 02\/2013. Sanofi-Aventis, Quebec, Canada."},{"key":"10.1016\/j.yebeh.2015.02.009_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0165","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa(\u00ae)) after co-medication with verapamil in healthy subjects","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0170","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"H\u00e4rtter","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0180","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2125.2006.02587.x","article-title":"Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements","volume":"62","author":"Owen","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.009_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2008.10.014","article-title":"Patients with epilepsy's perception on community pharmacist's current and potential role in their care","volume":"14","author":"McAuley","year":"2009","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T22:14:17Z","timestamp":1566425657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":37,"alternative-id":["S1525505015000578"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.009","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug interactions involving antiepileptic drugs: Assessment of the consistency among three drug compendia and FDA-approved labels","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}